ArticleAnatomy & cell biology2025
Silencing serine/arginine-rich splicing factor 1 to induce apoptosis and autophagy-dependent cell death in cholangiocarcinoma through the correction of oncogenic splicing errors.
Article in Anatomy & cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CCA) is a bile duct cancer often linked to liver fluke infections. In Thailand, it has a high incidence and mortality rate due to imprecise symptoms, late diagnosis, and limited treatments. Our previous research identified gene-splicing errors as a factor in CCA progression. This study focused on the role of serine/arginine-rich splicing factors (SRSFs) in CCA. SRSF1-SRSF12 expressions were analyzed using reverse transcription polymerase chain reaction (RT-PCR), confirming upregulation with RT quantitative PCR, western blotting, and dataset analysis. One SRSF was selected for silencing in CCA cell lines (KKU-055 and KKU-213A) using small interfering RNAs. Cell proliferation and survival were assessed through various assays, while apoptosis and autophagy markers were analyzed using western blotting, immunofluorescence, RT-PCR, and transmission electron microscopy (TEM). Splicing errors in death-related genes were also examined. The results showed that SRSF1 was significantly overexpressed in CCA, especially among gastrointestinal cancers. Silencing SRSF1, particularly in KKU-213A cells, reduced cell proliferation and increased cell death. Apoptosis was marked by increased caspase-3 and BAX, decreased Bcl-2, and cytochrome C release. Autophagy was indicated by a higher LC3B-II/LC3B-I ratio, lower p62, and increased
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.